================================================================================
                                  UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                     Form 10-Q

(Mark One)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934

For the quarterly period ended June 30, 1999, or

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
    Exchange Act of 1934

For the transition period from _________________ to __________________

Commission file number      000-21615
                           ------------


                             BOSTON BIOMEDICA, INC.
           (Exact name of Registrant as Specified in its Charter)

     Massachusetts                                   04-2652826
------------------------                       ----------------------
    (State or other                               (I.R.S. Employer
    Jurisdiction of                               Identification No.)
      Incorporation or
     Organization)

   375 West Street,
   West Bridgewater,
     Massachusetts                                   02379-1040
------------------------                       ----------------------
 (Address of Principal                              (Zip Code)
  Executive Offices)

Registrant's telephone number, including area code    (508) 580-1900
                                                      --------------

         Indicate  by check  whether the  registrant:  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                                         Yes [X]         No [ ]

         The  number of shares  outstanding  of the  Registrant's  only class of
common stock as of July 31, 1999 was 4,770,153.

================================================================================
<PAGE>

Part I. Financial Information

Item 1. Financial Statements



                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                        CONSOLIDATED STATEMENTS OF INCOME

                                   (Unaudited)
<TABLE>
<CAPTION>
                                                  For the Three Months Ended      For the Six Months Ended
                                                           June 30,                       June 30,
                                                 -----------------------------  -----------------------------
                                                     1999           1998            1999           1998
                                                 -------------  --------------  -------------  --------------

REVENUE:
<S>                                              <C>             <C>            <C>             <C>
     Products                                     $ 3,491,323     $ 3,316,804    $ 6,947,525     $ 6,380,163
     Services                                       3,647,334       3,066,328      7,036,297       6,275,764
                                                 -------------  --------------  -------------  --------------
            Total revenue                           7,138,657       6,383,132     13,983,822      12,655,927

COSTS AND EXPENSES:
     Cost of product sales                          1,822,537       1,674,837      3,631,184       3,446,588
     Cost of services                               2,641,555       1,999,019      5,111,652       4,322,230
     Research and development                         728,452         583,592      1,491,061       1,015,981
     Acquired research and development                 -              -               -              850,000
     Selling and marketing                          1,102,546         926,015      2,107,817       1,854,627
     General and administrative                     1,116,975         983,075      2,211,665       2,013,011
                                                 -------------  --------------  -------------  --------------
            Total operating costs and expenses      7,412,065       6,166,538     14,553,379      13,502,437

            (Loss) income from operations            (273,408)        216,594       (569,557)       (846,510)

Interest income                                           159           3,666            855          28,195
Interest expense                                      (89,549)         (4,326)      (176,748)         (5,296)
                                                 -------------  --------------  -------------  --------------

            (Loss) income before income taxes        (362,798)        215,934       (745,450)       (823,611)

Benefit from (provision for) income taxes             137,863         (82,055)       283,270         312,972
                                                 -------------  --------------  -------------  --------------

            Net (loss) income                      $ (224,935)      $ 133,879     $ (462,180)     $ (510,639)
                                                 =============  ==============  =============  ==============

            Net (loss) income per share, basic        $ (0.05)         $ 0.03        $ (0.10)        $ (0.11)
            Net (loss) income per share, diluted      $ (0.05)         $ 0.03        $ (0.10)        $ (0.11)

Number of shares used to calculate net income per share
            Basic                                   4,743,870       4,652,519      4,680,915       4,642,343
            Diluted                                 4,743,870       4,865,593      4,680,915       4,642,343

</TABLE>

                 See Notes to Consolidated Financial Statements

                                       2

<PAGE>


                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                             June 30,      December 31,
                                                                               1999            1998
                                                                           -------------   --------------

                               ASSETS
CURRENT ASSETS:
<S>                                                                        <C>              <C>
    Cash and cash equivalents                                                 $ 253,610        $ 146,978
    Accounts receivable, less allowances of $725,693 in 1999 and
       $623,710 in 1998                                                       5,328,779        6,086,693
    Inventories                                                               6,780,350        6,689,768
    Prepaid expense and other                                                   693,177          479,983
    Deferred income taxes                                                       900,581          847,268
                                                                           -------------   --------------
                Total current assets                                         13,956,497       14,250,690
                                                                           -------------   --------------

Property and equipment, net                                                   7,503,731        6,925,423

OTHER ASSETS:
    Goodwill and other intangibles, net                                       2,698,943        2,809,825
    Notes receivable and other                                                   88,552           96,447
                                                                           -------------   --------------
                                                                              2,787,495        2,906,272
                                                                           -------------   --------------
              TOTAL ASSETS                                                 $ 24,247,723     $ 24,082,385
                                                                           =============   ==============


                LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
    Accounts payable                                                        $ 2,007,073      $ 2,369,495
    Accrued compensation                                                      1,350,135        1,284,162
    Other accrued expenses                                                      814,527          795,642
    Current maturities of long term debt                                         16,343           15,569
    Deferred revenue                                                               -             690,760
                                                                           -------------   --------------
                Total current liabilities                                     4,188,078        5,155,628
                                                                           -------------   --------------

LONG-TERM LIABILITIES:
    Long term debt, less current maturities                                   5,620,094        3,988,602
    Other liabilities                                                           493,802          730,138
    Deferred income taxes                                                       167,021          139,363

STOCKHOLDERS' EQUITY:
    Common stock, $.01 par value; authorized 20,000,000 shares in
       1999 and 1998; issued and outstanding 4,768,241 in 1999 and
       4,667,816 in 1998                                                         47,682           46,678
    Additional paid-in capital                                               16,589,967       16,418,717
    Accumulated deficit                                                      (2,858,921)      (2,396,741)
                                                                           -------------   --------------
                Total stockholders' equity                                   13,778,728       14,068,654
                                                                           -------------   --------------
             TOTAL LIABILITIES & STOCKHOLDERS' EQUITY                      $ 24,247,723     $ 24,082,385
                                                                           =============   ==============

</TABLE>

                 See Notes to Consolidated Financial Statements

                                       3

<PAGE>



                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF CASH FLOWS

                                   (Unaudited)


                                                      For the Six Months Ended
                                                              June 30,
                                                    ----------------------------
                                                        1999           1998
                                                    -------------  -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
    Net loss                                          $ (462,180)    $ (510,639)
    Adjustments to reconcile net loss to net
       cash used in operating activities:
    Depreciation and amortization                        722,090        607,252
    Provision for doubtful accounts                       54,268        103,036
    Deferred rent and other liabilities                 (236,336)       132,386
    Deferred income taxes                                (25,655)       (56,342)
    Acquired research and development                          -        850,000
Changes in operating assets and liabilities:
    Accounts receivable                                  703,646       (108,025)
    Inventories                                          (90,582)      (700,592)
    Prepaid expenses                                    (213,194)      (352,074)
    Accounts payable                                    (362,422)      (568,340)
    Accrued compensation and other expenses               84,858       (102,742)
    Deferred revenue                                    (690,760)      (364,707)
                                                    -------------  -------------
        Net cash used in operating activities           (516,267)    (1,070,787)
                                                    -------------  -------------

CASH FLOWS FROM INVESTING ACTIVITIES:
    Acquired research and development                          -       (850,000)
    Additions to property and equipment               (1,189,516)    (1,325,343)
    Advances under notes receivable and other assets       7,895         15,813
                                                    -------------  -------------
        Net cash used in investing activities         (1,181,621)    (2,159,530)
                                                    -------------  -------------

CASH FLOWS FROM FINANCING ACTIVITIES:
    Proceeds from long term debt                       1,639,862        515,751
    Repayments of long-term debt                          (7,596)        (6,892)
    Proceeds of common stock issued                      172,254         72,625
                                                    -------------  -------------
        Net cash provided by financing activities      1,804,520        581,484
                                                    -------------  -------------

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS:        106,632     (2,648,833)
    Cash and cash equivalents, beginning of period       146,978      2,772,360
                                                    -------------  -------------
    Cash and cash equivalents, end of period           $ 253,610      $ 123,527
                                                    =============  =============


                 See Notes to Consolidated Financial Statements

                                       4
<PAGE>


                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)     Basis of Presentation

         The accompanying  unaudited consolidated financial statements have been
prepared in accordance  with generally  accepted  accounting  principles for the
interim financial information and with the instructions to Form 10-Q and Article
10 of Regulation  S-X.  Accordingly,  they do not include all of the information
and footnotes required by generally accepted accounting  principles for complete
financial statements. In the opinion of management,  all adjustments (consisting
of  only  normal  recurring   adjustments)   considered  necessary  for  a  fair
presentation have been included.  Operating results for the three and six months
ended June 30, 1999 are not  necessarily  indicative  of the results that may be
expected for the year ending December 31, 1999. For further  information,  refer
to the consolidated  financial  statements and footnotes thereto included in the
Annual  Report on Form 10-K for the fiscal  year  ended  December  31,  1998 for
Boston Biomedica,  Inc. and Subsidiaries ("the Company" or "Boston  Biomedica").
Certain prior year amounts in the  consolidated  financial  statements  may have
been reclassified to conform to the current year's presentation.

(2)     Use of Estimates

         In conformity with generally accepted accounting principles, management
is required to make estimates and assumptions  that affect the reported  amounts
of assets,  liabilities,  revenues, and expenses for the periods presented. Such
estimates include reserves for uncollectable  accounts receivable as well as the
net  realizable  value of its  inventory.  Actual  results could differ from the
estimates and assumptions used by management.

(3)     Inventories

    Inventories consisted of the following:

                                           June 30,        December 31,
                                             1999              1998
                                        ---------------   ----------------

Raw materials                              $ 2,658,391        $ 2,407,154
Work-in-process                              1,612,164          1,788,399
Finished goods                               2,509,795          2,494,215
                                        ---------------   ----------------
                                           $ 6,780,350        $ 6,689,768
                                        ===============   ================


(4) Segment Reporting and Related Information (all dollar amounts in thousands)

         Selected  summarized  results for the Company's four operating segments
are as follows:

<TABLE>
<CAPTION>
                                                Three Months Ended June 30,       Six Months Ended June 30,
Segment revenue:                                    1999            1998             1999            1998
----------------                                -------------   -------------    -------------   -------------
<S>                                             <C>             <C>              <C>             <C>
Diagnostics                                          $ 4,019         $ 3,886          $ 7,942         $ 7,505
Clinical Laboratory Services                           2,464           1,725            4,669           3,311
Laboratory Instrumentation                               892           1,006            1,925           2,205
Other                                                     84               -               84               -
Eliminations                                            (320)           (234)            (636)           (365)
                                                -------------   -------------    -------------   -------------
   Total revenue                                     $ 7,139         $ 6,383         $ 13,984        $ 12,656
                                                =============   =============    =============   =============

</TABLE>

<TABLE>
<CAPTION>
                                                Three Months Ended June 30,       Six Months Ended June 30,
Segment operating (loss) income:                    1999            1998             1999            1998
--------------------------------                -------------   -------------    -------------   -------------
<S>                                            <C>             <C>              <C>             <C>
Diagnostics                                            $ 195           $ 345            $ 274           $ 293
Clinical Laboratory Services                             134              36              280             105
Laboratory Instrumentation                              (215)            (99)            (349)           (297)
Other                                                   (387)            (65)            (775)            (98)
Acquired R&D                                               -               -                -            (850)
                                                -------------   -------------    -------------   -------------
   Total (loss) income from operations                $ (273)          $ 217           $ (570)         $ (847)
                                                =============   =============    =============   =============
</TABLE>



                                       5

<PAGE>
                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


(4)  Segment Reporting and Related Information (Continued)

                                                  June 30,        Dec. 31,
Identifiable segment assets:                        1999            1998
----------------------------                    -------------   -------------
Diagnostics                                         $ 16,190        $ 16,548
Clinical Laboratory Services                           3,019           2,348
Laboratory Instrumentation                             4,060           4,428
Other                                                    979             758
                                                =============   =============
   Total assets                                     $ 24,248        $ 24,082
                                                =============   =============

(5)  Acquired Research and Development

         In March 1998,  the Company  acquired from BioSeq,  Inc.("BioSeq")  the
sole and exclusive  worldwide right to development stage  technology,  including
the use of BioSeq technical information,  licensed processes and improvements to
develop, manufacture,  market and sell or sublicense products or services in the
field of  human  in  vitro  immunodiagnostics.  In  accordance  with  accounting
standards for purchased  research and development,  costs totaling $850,000 were
expensed in that period.  In September  1998,  the Company  acquired 100% of the
remaining  stock of BioSeq in a purchase  transaction.  See the  Company's  most
recent  filing on Form 10-K for the year ended  December  31,  1998 for  further
information.

(6)  Computation of Net Income per Share

         The  following  illustrates  the  computation  of basic and diluted net
income per share.

<TABLE>
<CAPTION>
                                            Three Months Ended June 30, Six Months Ended June 30,
                                               1999          1998          1999          1998
                                            -----------   -----------   -----------   -----------

<S>                                        <C>           <C>           <C>           <C>
Weighted average common stock outstanding    4,743,870     4,652,519     4,680,915     4,642,343

Net effect of dilutive common stock
   equivalents-based on treasury stock
   method using average market price *               -       213,074             -             -

                                            -----------   -----------   -----------   -----------
                                             4,743,870     4,865,593     4,680,915     4,642,343
                                            ===========   ===========   ===========   ===========



Net (loss) income, basic and diluted        $ (224,935)    $ 133,879    $ (462,180)   $ (510,639)
                                            ===========   ===========   ===========   ===========


Net (loss) income per share                      (0.05)         0.03         (0.10)        (0.11)
                                            ===========   ===========   ===========   ===========
</TABLE>


         *  Potentially  dilutive  securities of 157,678 and 228,875 and 231,602
         were not included in the computation of diluted  earnings per share for
         the six months  ended June 30,  1999 and 1998 and for the three  months
         ended  June 30,  1999,  respectively  because  to do so would have been
         antidilutive.

                                       6

<PAGE>
                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



(7)  The Amended Line of Credit Agreement

         Effective June 30, 1999, the Company entered into an amended  revolving
line of credit  agreement  (the "Amended  Line") with its bank,  increasing  the
facility to $10 million  from $7.5  million.  The Amended  Line matures June 30,
2001;  bears interest at the Company's option based on either the base rate plus
1/4% or LIBOR  plus  2.75%;  carries a facility  fee of 1/4% per annum,  payable
quarterly;  and is  collateralized by substantially all of the assets (excluding
real property) of the Company.  Borrowings under the Amended Line are limited to
commercially   standard  percentages  of  accounts  receivable,   inventory  and
equipment.  The Company had approximately  $460,000  available under the Amended
Line as of June 30, 1999.

         The Amended Line  contains  covenants  regarding  the  Company's  total
liabilities to tangible net worth ratio,  minimum debt service  coverage  ratio,
and maximum net loss. The Amended Line further  provides for restrictions on the
payment  of  dividends,  incurring  additional  debt,  and the amount of capital
expenditures.

                                       7

<PAGE>





Item 2.  Management's Discussion and Analysis of Results of Operations and
         Financial Condition.

Three Months Ended June 30, 1999 and 1998

         Total revenue  increased  11.8% or $756,000 to $7,139,000 for the three
months  ended  June 30,  1999 from  $6,383,000  in the prior year  period.  This
increase was the result of an increase in product sales of 5.3%, or $174,000, to
$3,491,000  and an  increase  in  specialty  laboratory  services  of 18.9%,  or
$581,000,  to  $3,647,000.  The  increase  in product  revenue was the result of
continued  strong sales of quality control  products other than OEM panels.  The
increase in service revenue was the result of significant  increases in clinical
laboratory testing including nucleic acid (molecular) testing for HIV, Hepatitis
C and Lyme Disease.

         Gross profit decreased 1.3%, or $34,000,  to $2,675,000 for the current
three  months from  $2,709,000  in the prior year period.  Overall  gross margin
decreased  to 37.5% from 42.4%.  The  decrease  was  primarily  attributable  to
services.  The gross margin on services  decreased  to 27.6% from 34.8%,  as the
Company  used an  aggressive  pricing  strategy  to  capture  a  portion  of its
increased clinical laboratory testing revenue.

         Research and development  expenses  increased  24.8%,  or $145,000,  to
$728,000 for the current  three  months from  $584,000 in the prior year period.
The  increase is  primarily  the result of  increased  spending  on  development
efforts  in  pressure  cycling  technology  ("PCT").  Also  contributing  to the
increase  was  continued  spending on new  molecular  tests and Quality  Control
Products.

         Selling  and  marketing  expenses  increased  19.1%,  or  $177,000,  to
$1,103,000  for the current three months from $926,000 in the prior year period.
This increase was primarily  the result of increased  promotion  expenses at BBI
Diagnostics.

         General and administrative  expenses  increased 13.5%, or $133,000,  to
$1,117,000  for the current three months from $984,000 in the prior year period.
The increase  primarily relates to increased  business  development and investor
relations activities.

         Net interest  expense was $89,390 for the current  quarter  compared to
$660 in the prior year period. The Company completed  significant  investment in
technology and  infrastructure  during the first half of 1998, thereby utilizing
its cash available to invest.  Since mid-1998,  capital  expenditures  have been
funded primarily through the Company's line of credit.

         The  Company  recorded  a tax  benefit  in both  quarters  based on the
combined federal and state statutory rate of 38%.

Six Months Ended June 30, 1999 and 1998

         Total revenue  increased  10.5%, or $1,328,000,  to $13,984,000 for the
six months ended June 30, 1999 from  $12,656,000 in the prior year period.  This
increase was the result of an increase in product sales of 8.9%, or $567,000, to
$6,948,000  and an  increase  in  specialty  laboratory  services  of 12.1%,  or
$761,000,  to  $7,036,000.  The increase in product  revenue is due to continued
strong  Accurun(R)  sales and a significant  increase in  laboratory  instrument
sales. The increase in specialty  laboratory services is primarily  attributable
to increases in clinical laboratory testing.

         Gross profit increased 7.2%, or $354,000, to $5,241,000 for the current
six months from  $4,887,000  in the prior year period.  The gross profit  margin
decreased  to 37.5% for the  current six months  versus  38.6% in the prior year
period.  This decrease is due primarily to lower margins on clinical  laboratory
testing services.

         Research and development  expenses  increased  46.8%,  or $475,000,  to
$1,491,000 for the current six months from  $1,016,000 in the prior year period.
The increase is primarily the result of development  efforts in PCT and the drug
development  program as well as additional  spending on new molecular  tests and
Quality Control Products.

                                       8

<PAGE>

         There was a one time  accounting  charge of  $850,000,  in the  quarter
ended March 31, 1998,  related to the  acquisition  of the  worldwide  exclusive
rights to BioSeq, Inc.'s immunodiagnostic research and development technology.

         Selling  and  marketing  expenses  increased  13.7%,  or  $253,000,  to
$2,108,000 for the current six months from  $1,855,000 in the prior year period.
The increase was attributable primarily to increased promotion expenditures.

         General and  administrative  expenses  increased 9.9%, or $199,000,  to
$2,212,000 for the current six months from  $2,013,000 in the prior year period.
This  increase  was a result of  increased  business  development  and  investor
relations activities.

         Net interest  expense of ($176,000)  was incurred in 1999 versus income
of  $23,000  for the  prior  year  period.  The  Company  completed  significant
investment  in  technology  and  infrastructure  during  the first half of 1998,
thereby  utilizing  its  cash  available  to  invest.  Since  mid-1998,  capital
expenditures have been funded primarily through the Company's line of credit.

         The  Company  recorded  a tax  benefit  in both  periods  based  on the
combined federal and state statutory rate of 38%.

Liquidity and Financial Condition

         At June  30,  1999,  the  Company  had cash  and  cash  equivalents  of
approximately  $254,000  and  working  capital  of  $9,768,000.  Trade  accounts
receivable  decreased  $704,000 as a result of strong  collections in the second
quarter.  Inventory  increased  $91,000  primarily  due  to a  higher  level  of
Basematrix and OEM panel orders at BBI Diagnostics.

         The Company has financed its  operations to date through cash flow from
operations, borrowings from its bank and the sale of its common stock. Effective
June 30,  1999,  the  Company  reached  agreement  with its bank to  expand  its
revolving  line of credit to $10 million  (from $7.5  million).  See  Footnote 7
regarding the Amended Line. The Company expects its cash flow,  working capital,
and available borrowings under its Amended Line to meet existing operational and
capital needs for the next twelve months.


         Net cash used in operations  for the six months ended June 30, 1999 was
$516,000 as compared to  $1,071,000  in the prior year period.  This increase in
cash flow was primarily  attributable to stronger cash receipts  compared to the
prior year as well as reduced raw material purchases.

         Cash used in  investing  activities  for the six months  ended June 30,
1999 was $1,182,000 as compared to $2,160,000 in the prior year period. The cash
used relates to  expenditures  for  manufacturing,  laboratory  and  information
technology  equipment  as  well  as  continued  improvements  at  the  Company's
Massachusetts  and Maryland  facilities.  The 1998 amount includes  $850,000 for
acquired research and development. (See Footnote 5 above).

         Cash provided by financing activities for the six months ended June 30,
1999 was  $1,805,000  as  compared to  $581,000  in the prior year  period.  The
increase  was  primarily  related  to the  increased  debt  from  the  company's
revolving line of credit incurred to finance  additional  working capital needs,
and property and equipment additions.

         The Company anticipates significant capital expenditures to continue in
1999 and 2000 as it plans to complete renovations to its manufacturing  facility
in Massachusetts,  as well as implement a fully integrated business  information
system ("ERP") at all locations.  Except for purchase  orders in connection with
the  manufacturing  expansion and ERP system,  there were no material  financial
commitments for capital expenditures as of June 30, 1999.

                                       9

<PAGE>


Year 2000 Computer Systems Compliance

         The following  disclosure is a Year 2000 ("Y2K")  readiness  disclosure
statement pursuant to the Year 2000 Readiness and Disclosure Act.

         Boston  Biomedica's  Year 2000  program is  designed  to  minimize  the
possibility  of serious Year 2000  interruption.  Possible  Year 2000 worst case
scenarios  include  the  interruption  of  significant  parts  of the  Company's
business as a result of internal  business  system failure or the failure of the
business  systems  of  its  suppliers,   distributors  or  customers.  Any  such
interruption  may have a material  adverse  impact on the future  results of the
Company.

         In 1997 the Company  decided to  significantly  upgrade  its  "business
systems"  (all  computer  hardware  and  software  used  to run  its  businesses
including its  operations  management,  administration  and financial  systems).
Specifications  were  developed for desired  capabilities,  including  Year 2000
compliance.  In 1998 the Company  began  assessing  its Year 2000  exposure  and
commenced implementation of a plan to achieve Year 2000 readiness.  Based on its
review to date, the Company believes that its products are Year 2000 compliant.

         During  the  third  quarter  of  1998,  after   investigating   several
alternatives,  implementation  of an enterprise  resource  planning system ("ERP
system")  was  started  at two of the  Company's  four  sites.  The  vendor  has
certified  that the  system  is Year 2000  compliant.  In April  1999,  business
systems at the other two sites were upgraded to Y2K compliant  versions of their
existing software at a combined cost of approximately $5,000.

         A task  force  with  participants  and a site  leader  at each  Company
location have reviewed all other infrastructure  areas including  communications
systems,  building security systems, and embedded  technologies in areas such as
laboratory instruments and manufacturing  equipment.  The Company has also begun
to survey major suppliers,  distributors,  and customers to determine the status
and schedule for their Year 2000 compliance. To date, no significant issues have
been identified, and the survey is expected to be completed in the third quarter
of  1999.  Where  it  believes  that a  particular  supplier's  situation  poses
unacceptable risks, the Company plans to identify an alternative source.

         The  costs  of  the  readiness  program  for  business  systems,  other
infrastructure  areas,  and suppliers  and  distributors  are a  combination  of
incremental external spending and use of existing internal resources.  In total,
the Company expects to spend less than $150,000 to achieve  readiness,  of which
approximately  75% has been expended to date.  This amount is based on the costs
to upgrade the existing business systems to Y2K compliant versions, and excludes
the costs of implementing the ERP system which is being  implemented for reasons
beyond Y2K compliance.

         Milestones  and  implementation  dates and the costs of BBI's Year 2000
readiness  program are  subject to change  based on new  circumstances  that may
arise or new  information  becoming  available  that may change  the  underlying
assumptions or requirements.

Forward-Looking Statements

         This Quarterly Report on Form 10-Q contains forward-looking  statements
concerning the Company's  financial  performance  and business  operations.  The
Company  wishes to caution  readers of this  Quarterly  Report on Form 10-Q that
actual   results   might  differ   materially   from  those   projected  in  any
forward-looking statements.

         Factors that could cause actual results to differ from those  projected
include the possibility that due to unforeseen management, financial, technical,
and other difficulties,  reorganization of the Company's corporate structure and
management,  as  discussed in its July 22, 1999 Press  Release,  may not lead to
increased  profitability or R&D program acceleration.  Also, the Company may not
be able to develop its  research  and  development  programs  into  commercially
successful  products,  or  such  development  may  take  longer  than  currently
expected. Certain of these and other factors which might cause actual results to
differ  materially  from  those  projected  are more  fully set forth  under the
caption "Risk Factors" in the Company's  Annual Report on Form 10-K for the year
ended  December  31, 1998 and its  Quarterly  Report on Form 10-Q for the period
ended March 31, 1999.


                                       10

<PAGE>


    BOSTON BIOMEDICA, INC.

Part II. Other Information

Item 4. Submission of Matters to a Vote of Security Holders.

     None

Item 6.   Exhibits and Reports on Form 8K
(a)     Exhibits

       Exhibit No.
       -----------
       3.1      Amended and Restated Articles of Organization of the Company**

       3.2      Amended and Restated Bylaws of the Company**

       4.1      Specimen Certificate for Shares of the Company's Common Stock**

       4.2      Description  of  Capital  Stock  (contained  in  the  Restated
                Articles of  Organization of the Company filed as Exhibit 3.1)
                **

       27       Financial Data Schedule

------------------------

**     In accordance with Rule 12b-32 under the Securities Exchange Act of 1934,
       as amended,  reference is made to the documents previously filed with the
       Securities   and  Exchange   Commission,   which   documents  are  hereby
       incorporated by reference.

(b)     Reports on Form 8K

         None

                                       11

<PAGE>




                                   SIGNATURES



         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                             BOSTON BIOMEDICA, INC.



Date: August 16, 1999                  By /S/ Kevin W. Quinlan
      ------------------                 --------------------------------------
                                          Kevin W. Quinlan, President


                                       12
<PAGE>


                             BOSTON BIOMEDICA, INC.

                                  EXHIBIT INDEX

EXHIBIT INDEX
-------------

     Exhibit No.                                                     Reference
     -----------                                                     ---------

     3.1    Amended and Restated Articles of Organization of the        A**
            Company

     3.2    Amended and Restated Bylaws of the Company                  A**

     4.1    Specimen Certificate for Shares of the Company's            A**
            Common Stock

     4.2    Description of Capital Stock (contained in the              A**
            Restated Articles of Organization of the Company
            filed as Exhibit 3.1)

     27     Financial Data Schedule                                    Filed
                                                                       herewith
------------------------

A    Incorporated by reference to the Company's  Registration  Statement on Form
     S-1 (Registration No. 333-10759)(the  "Registration Statement"). The number
     set  forth  herein  is the  number  of the  Exhibit  in  said  registration
     statement.
**   In accordance  with Rule 12b-32 under the Securities  Exchange Act of 1934,
     as amended,  reference is made to the documents  previously  filed with the
     Securities and Exchange Commission, which documents are hereby incorporated
     by reference.


                                       13